Related Experiment Video
Updated: Sep 2, 2025
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
Published on: September 28, 2022
Epstein-Barr virus-associated smooth muscle tumors in immunocompromised patients: Six case reports
Afshin A Khan1, Bassam N Estfan2, Anirudh Yalamanchali3
1Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, United States. khana13@ccf.org.
Background:
Epstein-Barr virus associated smooth muscle tumor (EBV-SMT) is a rare oncological entity. However, there is an increasing incidence of EBV-SMTs, as the frequency of organ transplantation and immunosuppression grows. EBV-SMT diagnosis relies on histopathology and immunochemical staining to distinguish it from post-transplant lymphoproliferative disorder (PTLD). There is no clear consensus on the treatment of EBV-SMTs. However, surgical resection, chemotherapy, radiation therapy, and immunosuppression reduction have been explored with varying degrees of success.
Case Summary:
Our case series includes six cases of EBV-SMTs across different age groups, with different treatment modalities, adding to the limited existing literature on this rare tumor. The median latency time between immunosuppression and disease diagnosis is four years. EBV-SMTs present with variable degrees of aggressiveness and seem to have worse clinical outcomes in patients with tumor multiplicity and worse immunocompetency.
Conclusion:
It is imperative to continue building on this knowledge and keeping EBV-SMTs on the differential in immunocompromised individuals.
